407 related articles for article (PubMed ID: 30223097)
1. Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; Effects independent of Substance P.
Nizam E; Erin N
Biomed Pharmacother; 2018 Dec; 108():263-270. PubMed ID: 30223097
[TBL] [Abstract][Full Text] [Related]
2. NK1R antagonist decreases inflammation and metastasis of breast carcinoma cells metastasized to liver but not to brain; phenotype-dependent therapeutic and toxic consequences.
Nizam E; Köksoy S; Erin N
Cancer Immunol Immunother; 2020 Aug; 69(8):1639-1650. PubMed ID: 32322911
[TBL] [Abstract][Full Text] [Related]
3. Substance P Receptor Antagonist Suppresses Inflammatory Cytokine Expression in Human Disc Cells.
Kepler CK; Markova DZ; Koerner JD; Mendelis J; Chen CM; Vaccaro AR; Risbud MV; Albert TJ; Anderson DG
Spine (Phila Pa 1976); 2015 Aug; 40(16):1261-9. PubMed ID: 25929203
[TBL] [Abstract][Full Text] [Related]
4. Roles of full-length and truncated neurokinin-1 receptors on tumor progression and distant metastasis in human breast cancer.
Zhou Y; Zhao L; Xiong T; Chen X; Zhang Y; Yu M; Yang J; Yao Z
Breast Cancer Res Treat; 2013 Jul; 140(1):49-61. PubMed ID: 23807418
[TBL] [Abstract][Full Text] [Related]
5. Autocrine control of MIP-2 secretion from metastatic breast cancer cells is mediated by CXCR2: a mechanism for possible resistance to CXCR2 antagonists.
Erin N; Nizam E; Tanrıöver G; Köksoy S
Breast Cancer Res Treat; 2015 Feb; 150(1):57-69. PubMed ID: 25682075
[TBL] [Abstract][Full Text] [Related]
6. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
7. Neurokinin 1 and 2 receptors are involved in PGE
Zhuang J; Gao X; Zhao L; Wei W; Xu F
Respir Physiol Neurobiol; 2022 Dec; 306():103952. PubMed ID: 35905863
[TBL] [Abstract][Full Text] [Related]
8. Role of PKC-delta on substance P-induced chemokine synthesis in pancreatic acinar cells.
Ramnath RD; Sun J; Adhikari S; Zhi L; Bhatia M
Am J Physiol Cell Physiol; 2008 Mar; 294(3):C683-92. PubMed ID: 18160487
[TBL] [Abstract][Full Text] [Related]
9. Effects of intravenous administration of neurokinin receptor subtype-selective agonists on gonadotropin-releasing hormone pulse generator activity and luteinizing hormone secretion in goats.
Yamamura T; Wakabayashi Y; Ohkura S; Navarro VM; Okamura H
J Reprod Dev; 2015; 61(1):20-9. PubMed ID: 25345909
[TBL] [Abstract][Full Text] [Related]
10. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential.
Herpfer I; Lieb K
CNS Drugs; 2005; 19(4):275-93. PubMed ID: 15813642
[TBL] [Abstract][Full Text] [Related]
11. NK1R/5-HT1AR interaction is related to the regulation of melanogenesis.
Wu H; Zhao Y; Huang Q; Cai M; Pan Q; Fu M; An X; Xia Z; Liu M; Jin Y; He L; Shang J
FASEB J; 2018 Jun; 32(6):3193-3214. PubMed ID: 29430989
[TBL] [Abstract][Full Text] [Related]
12. Substance P enhances the local activation of NK
Jeong YM; Cheng XW; Lee KH; Lee S; Cho H; Kim W
BMC Mol Cell Biol; 2020 Jun; 21(1):41. PubMed ID: 32517655
[TBL] [Abstract][Full Text] [Related]
13. Are biological actions of neurokinin A in the adult brain mediated by a cross-talk between the NK1 and NK2 receptors?
Tauer U; Zhao Y; Hunt SP; Culman J
Neuropharmacology; 2012 Nov; 63(6):958-65. PubMed ID: 22771977
[TBL] [Abstract][Full Text] [Related]
14. Tachykinin NK1 receptor antagonist L-733,060 and substance P deletion exert neuroprotection through inhibiting oxidative stress and cell death after traumatic brain injury in mice.
Li Q; Wu X; Yang Y; Zhang Y; He F; Xu X; Zhang Z; Tao L; Luo C
Int J Biochem Cell Biol; 2019 Feb; 107():154-165. PubMed ID: 30593954
[TBL] [Abstract][Full Text] [Related]
15. A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas.
Akazawa T; Kwatra SG; Goldsmith LE; Richardson MD; Cox EA; Sampson JH; Kwatra MM
J Neurochem; 2009 May; 109(4):1079-86. PubMed ID: 19519779
[TBL] [Abstract][Full Text] [Related]
16. Deciphering specificity and cross-reactivity in tachykinin NK1 and NK2 receptors.
Madsen JJ; Petersen JE; Christensen DP; Hansen JB; Schwartz TW; Frimurer TM; Olsen OH
J Biol Chem; 2023 Dec; 299(12):105438. PubMed ID: 37944618
[TBL] [Abstract][Full Text] [Related]
17. Receptors mediating tachykinin-evoked depolarisations of neurons in the neonatal rat spinal cord.
Fox AJ; Naeem S; Patel IA; Walpole C; Urbán L
Acta Biol Hung; 1996; 47(1-4):129-44. PubMed ID: 9123986
[TBL] [Abstract][Full Text] [Related]
18. Substance P (SP) enhances CCL5-induced chemotaxis and intracellular signaling in human monocytes, which express the truncated neurokinin-1 receptor (NK1R).
Chernova I; Lai JP; Li H; Schwartz L; Tuluc F; Korchak HM; Douglas SD; Kilpatrick LE
J Leukoc Biol; 2009 Jan; 85(1):154-64. PubMed ID: 18835883
[TBL] [Abstract][Full Text] [Related]
19. Substance P-induced cyclooxygenase-2 expression in human umbilical vein endothelial cells.
Gallicchio M; Rosa AC; Benetti E; Collino M; Dianzani C; Fantozzi R
Br J Pharmacol; 2006 Mar; 147(6):681-9. PubMed ID: 16432508
[TBL] [Abstract][Full Text] [Related]
20. The antiproliferative action of [D-Arg(1), D-Phe(5), D-Trp(7,9), LEU(11)] substance P analogue antagonist against small-cell- and non-small-cell lung cancer cells could be due to the pharmacological profile of its tachykinin receptor antagonist.
Munoz M; Recio S; Rosso M; Redondo M; Covenas R
J Physiol Pharmacol; 2015 Jun; 66(3):421-6. PubMed ID: 26084224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
